Continuous therapy in HHV-8 negative Multicentric Castleman Disease and prolonged progression-free survival.

ABSTRACT: The optimal treatment endpoints and duration of continuous therapy for multicentric Castleman disease (MCD) remain controversial. We retrospectively analyzed data from 123 patients with Human Herpesvirus (HHV)-8 negative MCD. We demonstrated that continuous therapy significantly enhanced progression-free survival (PFS) in patients who achieved an optimal response after initial treatment. These findings underscore the critical role of continuous therapy in HHV-8 negative MCD. Further studies with larger cohorts are required to validate these findings.

SUBMITTER: Liu Y 

PROVIDER: S-EPMC11304649 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature